Stark declines to enhance Idenix’s record $2.5bn patent damages award
District of Delaware says additional sanction is not warranted in Idenix v Gilead “given that the result of that misconduct is a cure for a potentially-fatal disease afflicting millions of people around the world, and given that the jury's damages award is already the largest damages verdict ever returned in a patent trial”
The District of Delaware has denied Idenix’s
request to enhance the damages of $2.54 it was awarded for
Gilead infringing its patents related to Hepatitis C drugs,
which was the largest ever patent damages award in the US.
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.